TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06493552: Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Sponsor: Vasgene Therapeutics, Inc · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 700 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT06493552 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06493552 Rescue Dossier →